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Abstract
Background & Aims—Inflammatory bowel disease (IBD) has familial aggregation in African 
Americans (AAs), but little is known about the molecular genetic susceptibility. Mapping studies 
using the Immunochip genotyping array expand the number of susceptibility loci for IBD in 
Caucasians to 163, but the contribution of the 163 loci and European admixture to IBD risk in 
AAs is unclear. We performed a genetic mapping study using the Immunochip to determine 
whether IBD susceptibility loci in Caucasians also affect risk in AAs and identify new associated 
loci.
Methods—We recruited AAs with IBD and without IBD (controls) from 34 IBD centers in the 
US; additional controls were collected from 4 other immunochip studies. Association and 
admixture loci were mapped for 1088 patients with Crohn's disease (CD), 361 with ulcerative 
colitis (UC), 62 with IBD type-unknown (IBDU), and 1797 controls; 130,241 autosomal single-
nucleotide polymorphisms (SNPs) were analyzed.
Results—The strongest associations were observed between UC and HLA rs9271366 (P=7.5e–
6), CD and 5p13.1 rs4286721 (P=3.0e–6), and IBD and KAT2A rs730086 (P=2.3e–6). Additional 
suggestive associations (P<4.2e-5) were observed between CD and IBD and African-specific 
SNPs in STAT5A and STAT3; between IBD and SNPs in IL23R, IL12B, and C2 open reading 
frame 43; and between UC and SNPs near HDAC11 and near LINC00994. The latter 3 loci have 
not been previously associated with IBD, but require replication. Established Caucasian 
associations were replicated in AAs (P<3.1e-4) at NOD2, IL23R, 5p15.3, and IKZF3. Significant 
admixture (P<3.9e–4) was observed for 17q12-17q21.31 (IZKF3 through STAT3), 
10q11.23-10q21.2, 15q22.2–15q23, and 16p12.2–16p12.1. Network analyses showed significant 
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enrichment (false discovery rate <1e–5) in genes that encode members of the JAK–STAT, 
cytokine, and chemokine signaling pathways, as well those involved in pathogenesis of measles.
Conclusions—In a genetic analysis of 3308 AA IBD cases and controls, we found that many 
variants associated with IBD in Caucasians also showed association evidence with these diseases 
in AAs; we found evidence for loci and variants not previously associated with IBD. The complex 
genetic factors that determine risk for or protection from IBD in different populations require 
further study.
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Introduction
Inflammatory bowel disease (IBD) is a complex genetic disorder of immune dysregulation 
causing chronic idiopathic inflammation of the gastrointestinal tract, estimated to affect 
about 1.4 million Americans. It comprises two major, genetically related phenotypes: 
Crohn's disease (CD) and ulcerative colitis (UC).
IBD shares many clinical and immunological characteristics with other complex genetic 
immune-mediated diseases (IMDs), especially with seronegative auto-inflammatory 
diseases1, such as ankylosing spondylitis, psoriasis and primary immune-deficiencies2, 
indicating overlapping etiological factors. To facilitate genetic studies on IMDs a custom 
Illumina array of ~200,000 SNPs, the Immunochip, was designed based on genome wide 
association (GWA) analyses on Caucasian populations of 12 IMDs including IBD3. The 
main purposes were to fine map established associations and to replicate suggestive, but not 
yet proven, associations3. The Immunochip also contains ancestry informative markers 
(AIMs) allowing for genome-wide admixture estimates and adjustment for population 
stratification.
IBD GWA studies, including those performed using the Immunochip, have expanded the 
number of IBD susceptibility loci to 163 (including 30 CD- and 23 UC-specific loci)2, and 
have enhanced our understanding of IBD immunopathogenesis by identifying key cellular 
pathways, both known – such as barrier function, the role of T cell subsets and cytokine–
cytokine receptor signaling – and unknown – such as autophagy, regulation of interleukin 23 
(IL23) signaling, and host defense4. However, compared to hundreds of IBD genetic studies 
in Caucasian populations including massive GWA mega-analyses and replication studies 
like the Caucasian Immunochip Study (CIS)2, only a handful of IBD-associated gene 
variations have been evaluated in African Americans (AAs), in relatively small sample sizes 
of a few hundred cases and controls, and only for CD, not UC5-7.
AAs are a recently admixed population derived from an average of approximately 80% West 
African and 20% European ancestries8. IBD prevalence is lower in AAs than Caucasian 
Americans (CAs) possibly as a result of both genetic and environmental differences9-11. 
IBD sibling risk in AA IBD patients is relatively high (2.5%), suggesting underlying genetic 
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risk factors are in-part responsible for IBD in AAs, albeit lower than that observed for 
Caucasians (4.6%)12.
An admixed population is one where two or more previously separated populations have 
interbred. Loci that have different allele frequencies in the founder populations become 
correlated because of gene flow, a phenomenon known as admixture linkage disequilibrium 
(ALD). AAs are a typical example of an admixed population, where there has been recent 
introduction of European genetic lineages into a West-African-derived population. A 
powerful technique called mapping by ALD (MALD) can be used on admixed populations 
such as AAs and the underlying assumption is that the difference in disease frequency is due 
in part to differences in allele frequencies of causal variants between populations.
We therefore undertook an evaluation of the Immunochip in ~4000 AA IBD cases and 
controls, primarily to determine the importance of the 163 established CIS IBD loci in the 
understudied AA population and to identify novel IBD loci, including loci identified by 
MALD.
Patients and Methods
Study Population and Phenotyping
The study population included unrelated self-identified non-Hispanic AA volunteers 
recruited from three coordinating centers: (1) Johns Hopkins: Multicenter African American 
IBD Study (MAAIS) coordinated by Johns Hopkins IBD Genetics Research Center (GRC) 
of the NIDDK IBD Genetics Consortium (IBDGC) with recruitment from 13 collaborating 
IBD centers and 4 other IBDGC GRCs5, and additional AA control samples from the 
controls from rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and type 1 
diabetes (T1D) Immunochip studies; (2) Emory: GENESIS AA cohort, an ancillary study of 
the NIDDK IBDGC, coordinated by Emory University with recruitment of IBD cases and 
matched controls from 12 of their collaborating IBD centers; and (3) Cedars: Cedars-Sinai 
Medical Center recruited IBD cases and controls with additional controls from the 
Pharmacogenetics and Risk of Cardiovascular disease Study Group (PARC) from San 
Francisco General Hospital and University of California, Los Angeles13.
All subjects gave informed consent to participate in genetics research studies in protocols 
approved by each sites institutional review board. Cases were confirmed as CD, UC, or IBD 
type undetermined (IBDU) in accordance with the NIDDK IBDGC phenotyping manual14. 
Details regarding controls are described in the Supplement. See Acknowledgements for 
listing of all recruitment centers.
Genotyping and Quality Control (QC)
DNA samples were derived from whole blood. All DNA samples were genotyped using the 
Immunochip3 and genotype determinations (allele calls) were made using GenomeStudio 
version 2011.1 and Genotyping Module Version 1.9.4. All MAAIS samples and the RA, 
SLE, and T1D controls were genotyped at Feinstein Institute for Medical Research. All 
Emory, Cedars-Sinai and PARC samples were genotyped at Cedars-Sinai Medical Center 
Genetics Institute.
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Several SNP-wise and sample-wise quality filters were applied (Supplementary Figure 1). 
Samples were excluded if they had <99% data completeness, differed by >3 standard 
deviations from the mean heterozygosity for the study, had discrepant gender, or were 
unexpectedly the first-degree relative of any other sample in the study. Matching of cases 
and controls was done by determining principal components (PC) using the software 
EIGENSTRAT15, plotting PC1 against PC2, followed by visual inspection and elimination 
of outlier samples. Three successive rounds were necessary until a satisfactory matching of 
cases/controls (Supplementary Figure 2) was obtained.
Local and Global Ancestry Estimation
Because AAs are well-modeled as linear combinations of West African (YRI) and European 
(CEU) ancestries16, to estimate the locus-specific local ancestry, we chose the WINPOP 
model in LAMP package17 for its fast computation with low error rate18. Average West 
African (global YRI) ancestry was estimated by using ADMIXTURE19.
Study-wide Association and Admixture, and Replication of 163 SNPs Established in 
Caucasian Immunochip Study (CIS)
For all analyses, we compared three phenotypes, all IBD, CD, and UC, against the same set 
of AA controls. We performed association and admixture mapping both under generalized 
linear models. Sex, recruitment coordinating center (Hopkins, Emory or Cedars), GRC 
(Feinstein or Cedars), global YRI ancestry, and the first 10 PCs were included in multiple 
regression with IBD affection status, and those significantly associated with IBD were used 
as covariates in association and admixture mapping.
We estimated the testing burdens empirically by assessing the autocorrelation (of genotypes 
for association or local ancestry proportions for admixture) of all the SNPs on each 
autosomal chromosome for each individual, and then summing over the 22 chromosomes 
and averaging across individuals20.
The testing burdens of independent SNPs or admixture regions, specific to our dataset, were 
23,639.4 and 128.4 for association and admixture mapping respectively. Association peaks 
with p<2.1e-6 (5% false positive rate corrected for number of independent SNPs, i.e. 
0.05/23,639.4) were marked as significant, while those with 2.1e-6≤p<4.2e-5 were marked 
as suggestive (i.e. one false positive per study-wide test burden). Admixture peaks with 
p<3.9e-4 (0.05/128.4) were marked as significant.
For chromosomes with multiple significant/suggestive association SNPs, conditional 
regression was performed to determine number of independent signals. Specifically for m 
SNPs, all possible m*(m-1)/2 pairwise combinations were tested. For each pair if the target 
SNP remained significant in the presence of the conditional SNP then they are independent 
of each other; otherwise, they have arisen from the same signal.
To evaluate the 163 loci with reported genome-wide significance in the CIS, we tested the 
most statistically significant SNPs at each locus and present on the Immunochip (Maximal-
CIS SNPs). Criteria for replication was p<3.1e-4 (0.05/163).
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Gene Ontology was utilized to functionally annotate the genes within each significant 
admixture region, using the PANTHER Classification System (http://pantherdb.org). Genes 
with immunological or gastrointestinal-relevant functions were considered to be suggestive 
candidate genes within the region.
eQTL Evaluation
For significant/suggestive association SNPs we also performed local (cis-) and distant 
(trans-) expression quantitative trait locus (eQTL) mapping with R package MatrixEQTL21 
on peripheral blood mononuclear cells (PBMCs) drawn from a different set of 85 unrelated 
AA study subjects profiled with Illumina HumanHT-12 v4 Expression BeadChips and 
genotyped on Illumina HumanOmni1 or HumanOmni2.5 BeadChips22. We defined gene-
SNP pairs within 1Mb of another as local, otherwise distant, and those with false discovery 
rate (FDR) <0.05 were considered significant.
Network Analysis
We first selected genes with association p<0.005, and then the identified genes annotated 
with multiple biologically functional databases including Reactome23, human protein 
reference databases (www.hprd.org), and NCI/Nature Pathway Interaction Database. The 
networks were then constructed from the known interactions in those databases. In addition, 
we identified the top KEGG pathways associated with each network using the enrichment 
analysis tool in STRING (http://string-db.org/). See Supplement for additional details.
Results
After QC measures were performed, 3,308 samples (1,511 IBD cases and 1,797 controls) 
and 130,241 unique autosomal SNPs remained for association and admixture analyses 
(Supplementary Figures 1 and 2). Average West African ancestry was higher in controls 
than cases (81.7±9.7% vs. 80.0±10.3%, p<1e-5), and also differed by coordinating centers 
(p<1e-10), with YRI proportion lowest for AAs from the American West Coast, similar to 
other genetic studies24 (Supplementary Table 1).
Five variables were significantly associated with IBD (p<0.05) and therefore were included 
as covariates for all subsequent analyses: sex (p=5e-7), recruitment coordinating center 
(p=2e-5), GRC (p=4e-4), PC2 (p=0.015), and global ancestry (p=0.03). Quantile-quantile 
plots for association mappings and genomic inflation factors are shown in Supplementary 
Figure 3.
Replication of Maximal-CIS SNPs
152 of the 163 Maximal-CIS SNPs passed QC. The remaining 11 SNPs did not have any 
tagging (r2<0.6) SNPs that could be used as alternative markers. Five SNPs met criteria for 
replication (p<3.1e-4): rs5743289 that tags the three common NOD2 mutations, rs11209026 
that encodes the IL23R R381Q protective variant, rs1801274 that encodes the FCGR2A 
H167R risk variant, rs11742570 in the 5p13.1 gene desert near PTGER4 and rs12946510 on 
17q21 just 3’ of IKZF3 (Table 1).
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For most of the 152 SNPs, the AA odds ratios are in the same direction as those from the 
CIS (correlation=0.78, Figure 1). 81 SNPs had AA ORs within the 95% CIS confidence 
intervals (CI), including one replicated SNP (rs11742570). Nominal levels of significance 
(p<0.05 and same risk allele) were observed for 41 of the 152 (27%) variants 
(Supplementary Table 2).
Study-wide Association
Association results for IBD, CD and UC are shown in Figure 2 (left panels). Suggestive 
association for IBD was observed at the following 7 loci for 15 SNPs (Table 2): 1p at IL23R; 
2p near the p-telomere and 4 Mb upstream of an associated locus in the CIS near C2orf43; 
5p13.1 gene desert (5 SNPs in tight LD, pairwise r2 ranging from 0.52 to 1.00); 5q 70kb 
telomeric of IL12B (2 SNPs in tight LD, r2=0.87); and 17 in the STAT5A/STAT3 region (6 
SNPs in 3 LD blocks). Conditional regression revealed 3 independent signals from the latter 
region: three STAT5A SNPs (rs7220367, rs7217884 and rs13380828, all monomorphic in 
CEU, r2 ranging from 0.46 to 0.99) in one block; two SNPs 200 kb apart (rs730086 in 
KAT2A and rs1053004 in STAT3, r2=0.44); and rs7224339. IBD, being the phenotype with 
the largest sample size had greatest power to detect association evidence. However, 72% of 
cases had CD, and not surprisingly SNPs at 5p15.3 (PTGER4), IL12B, KAT2A and STAT5A 
also showed suggestive association for CD, with CD consistently showing greater 
association evidence at 5p15.3 than all IBD (Table 2).
For UC, the major peak located in the HLA region, with greatest association for rs9271366 
(p=7e-6). Conditional analysis revealed that all suggestive HLA SNPs could be accounted 
for by rs9271366 (Supplementary Figure 4). Two SNPs showed suggestive associations on 
chromosome 3, at 13Mb and at 64Mb (near HDAC11 and LINC00994), neither within 5Mb 
of any established IBD loci.
Raw genotyping intensities were visually examined for all replicated/suggestive SNPs and 
only rs35990859 (at IL12B) had sub-optimal cluster separation (data not shown).
Admixture Association
We observed four chromosomal regions of significant admixture association (Figure 2, right 
panels and Table 3) with all having significant evidence for both IBD and CD except for 
16p12 (IBD-only). For all of these regions, CEU (European) ancestry increases risk and YRI 
(West African) ancestry was protective. Just below significance was an area with increased 
CD risk from CEU, maximal at rs2111112 (p=4.9e-4) and 3 Mb from NOD2 (with increased 
CEU ALD extending through NOD2). Conditioning on NOD2 genotype rs5743289 
weakened this ALD evidence (p=0.017). A list of annotated genes with immune-related 
functions that map to each region is included in Supplementary Table 3.
eQTL Evaluation
We conducted PBMC eQTL mapping for 26 (5 significant replication and 21 suggestive 
study-wide association) SNPs with eQTL data. After controlling for multiple comparisons, 0 
distant and 6 local gene-SNP pairs showed significant association (Supplementary Table 4): 
rs1053004 on chromosome 17 was associated with KRT19 (p=1.7e-4) and with TTC25 
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(p=8.0e-4) expression; 3 SNPs (rs1876141 [p=5.5e-4], rs6866402 [p=7.5e-4], and 
rs1505994 [p=7.5e-4] in tight LD (r2>0.99) at 5p13.1 with Complement Component 6 (C6) 
expression; and rs1801274 with CD84 expression (p=1.2e-3). PTGER4 expression was 
evaluated but was not associated with any SNP evaluated (p>0.05).
Network Analysis
We found multiple networks demonstrating significant influence for IBD, CD and UC in 
AAs even after FDR and Bonferroni corrections (Table 4). Cytokine-cytokine receptor 
interaction was the dominant pathway for CD and IBD overall, but for UC was second in 
effect to Measles (which also played a significant but less prominent role in IBD and CD). 
Jak-STAT and Chemokine signaling pathways were included in top 3 networks for IBD and 
CD (and Jak-STAT alone for UC). In addition, T cell receptor signaling pathway was one of 
the top pathways in UC and IBD, but not CD.
Discussion
In this study of IBD genetics in the AA population, we assembled the largest set of cases 
and controls (more than 4 times larger than any prior AA IBD study and the first genetic 
study of AA UC), evaluated for replication the majority of established IBD associations and 
interrogated the majority of known IBD loci for novel associations, and performed pathway 
and eQTL analyses to further inform about the nature of AA IBD genetics. Although our 
genotyping platform (not being GWA) limited association mapping primarily to replicating 
known associations and interrogating established, immunologically related loci, we also 
used the more powerful method of MALD to identify novel loci throughout the autosomal 
genome and to complement the association mapping.
We replicated, using stringent criteria (p<3.1e-4), five CIS loci. As our study has more CD 
than UC cases, most of our replications were for CD. Not surprisingly we replicated loci 
with greater impact in other populations. Three of the five replications, NOD2, IL23R and 
5p13.1, account for the greatest degree of CD variance estimated in CIS. The two other 
replicated loci also have relatively high OR for Caucasian IBD: FCGR2A and IKZF3 (17th 
and 47th ranked ORs of the 163 CIS loci).
Two replicated CIS SNPs are more frequent in, and hence IBD risk is more likely to arise 
from, CEU than YRI genome: rs5743289 that tags the 3 common NOD2 CD-associated 
mutations rs12946510 at IKZF3 (Table 1). In contrast, the two other replicated SNPs, 
rs11742570 at 5p13.1 and the rs1801274 at FCGR2A with functional variant H167R, have 
similar presence in CEU and YRI genomes, whereas the R381Q wildtype albeit risk variant 
of IL23R at rs11209026 is more common in YRI than CEU genomes.
Given our sample size, we had 80% power to replicate Maximal-CIS SNPs with OR>1.3 
and MAF>0.2. Supplementary Figure 5 illustrates our power at different ORs/MAFs at three 
levels of significance. Although our study was underpowered a-priori for genome-wide 
association (and obtaining enough AA individuals for genetic studies, as statically powerful 
as those in Caucasians, may be impractical for years to come), we have identified SNPs in 
the AA population at a level of association for which to target for independent replication.
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Two replicated loci also had additional SNPs with suggestive association: 5p13.1 and 
IL23R. At 5p13.1 rs4286721 showed greatest association with CD (p=2.97e-6), only 
marginally below study-wide significance (p<2.1e-6). The suggestive SNPs are in LD, are 
protective and more frequent in YRI than CEU, and, in our PBMC eQTL analysis, 
correlated with complement component 6 (C6) instead of PTGER4, the associated gene in 
the original discovery in lymphoblastoid cell lines25. C6 is a reasonable candidate gene, 
given that C2 and other complement-related genes are associated with numerous IMDs. For 
rs7515029 at IL23R the protective allele is almost twice as frequent in YRI (9%) than CEU 
(5%) indicating another African-derived protective variant, in addition to the well-
established R381Q replication.
Our strongest UC signal was in the HLA region, similar to that observed in all examined 
populations. The most significant SNP, rs9271366, known to tag the HLA class II allele 
DRB1*1502 in other populations, is the same SNP found most statistically significant in 
both Japanese26 and Korean27 UC GWASs (p=1e-70 and p=1e-18 respectively). Hence, our 
rs9271366 UC association (p=7.47e-6) is justified as replication of an established UC SNP. 
It also accounted for nearby associations according to conditional analysis (Supplementary 
Figure 4). Interestingly, it was found to be the most associated HLA SNP in AA SLE, a 
disease 4-fold more frequent in AAs than CAs28.
The strongest IBD association was observed for rs730086, with OR=1.4 (p=2.26e-6, just 
below study-wide significance), at an intron of KAT2A, a histone acetyltransferase gene 
recently linked to repression of IFN-beta and innate antiviral immunity through inhibition of 
TKB129. In LD with rs730086 is rs1053004 (r2=0.44), located in the 3’utr of STAT3, which 
is eQTL for two genes (FDR=0.038): KRT19, a gene that produces a major type 1 keratin 
expressed in ileal and colonic epithelium with a broad distribution in simple and stratified 
epithelia; and TTC25, a gene important for celiogenesis expressed in bone marrow but not in 
intestine. The risk variants are much more frequent in CEU than YRI.
We observed two other independent signals for IBD and CD on chromosome 17 centered 
about STAT5A/STAT3 adjacent genes. These two signals are protective and African-specific 
(monomorphic in CEU). We found no association (p>0.1) for rs12942547, the CIS SNP 
located in STAT3 intron with nearly identical frequencies in CEU and YRI. Complementing 
these findings is significant ALD that overlaps this chromosome 17 region (and extends 
through IKZF3 and STAT3) with the CEU genome producing IBD risk and YRI being 
protective. Conditioning on the IKZF3 replicated SNP (rs11742570) and the 3 independent 
STAT5A/STAT3 associations eliminated this ALD (p=0.8). An important implication of our 
association and admixture results is that the common CEU STAT5A/STAT3 haplotype likely 
contributes to IBD risk in the Caucasians – a finding made possible by studying an admixed 
population. Sequencing studies in AAs will be important to identify potential functional 
variants in LD with the YRI-specific protective alleles.
We found three other regions with significant ALD. Although ALD regions should be 
unbiased to known loci (as Immunochip contained AIMs throughout the genome) all four 
regions overlap CIS loci. The most highly associated region is on chromosome 10, includes 
the IPMK/CISD1/UBE2D1/TFAM locus and extends to within 800 kb of ZNF365 (using a 
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genome-wide admixture p=0.10 cut-off). A region with ALD associated with CD and IBD 
on chromosome 15 contains SMAD3, a gene associated with need for multiple surgeries in 
CD30. A region on chromosome 16 contains PRKCB, IL4R and IL21R, and extends 
centromeric just to SBK1. Each of the ALD regions contains additional potential candidate 
genes, as noted in Supplementary Table 3.
The top three KEGG pathways in AA IBD (cytokine, Jak-STAT and chemokines) were 
among the top four KEGG pathways found in CIS. However, not observed in AA IBD was 
the Leishmania infection pathway – second most significant pathway in the CIS; whereas 
AA UC, IBD, and CD all showed strong evidence for measles pathway and UC also showed 
significant evidence for African trypanosomiasis – both pathways not observed in CIS.
The high frequency of genes associated with infectious disease supports the hypothesis that 
IBD genetic susceptibility may be a by-product of evolutionary adaption to human 
pathogens. Hence the differential infectious disease pathways associated with AA and 
Caucasian IBD may be related to adaptation to geographically distinct infectious diseases. In 
total, these findings suggest that, while major pathways are similar across populations, some 
are distinct and may be targets for personalized IBD therapies.
This first, in-depth characterization of AA IBD genetics provides a basis to compare IBD 
genetics with Caucasian2 and East Asian26,27,31-36 populations where multiple GWAS, 
replication and Immunochip studies have been performed (Figure 3). Five of the AA loci 
with suggestive/replication evidence are associated in all three populations: IL23R, 
FCGR2A, IL12B, HLA and STAT5A/3, with the functional SNPs for IL23R and FCGR2A the 
same. The higher OR loci tend to be observed in more than one population. The STAT5A/
STAT3 locus stands out in AAs: the ORs for the three independent associations are 0.76, 
1.40 and 0.55, suggesting that this region likely has a stronger influence in AA than 
Caucasian IBD (OR=1.1 for rs12942547 in CIS). A Japanese CD GWAS found relatively 
strong influence for STAT333, maximal at rs9891119, but we found no evidence in AAs for 
this SNP equally frequent in YRI, CEU and East Asians.
In summary, our study reveals that in AAs HLA SNPs demonstrate the dominant signal for 
UC; STAT5A/STAT3 shows disproportionate association with IBD and CD including novel 
African protective haplotypes and common European risk haplotypes that together with an 
IKZF3 CD replication 3 Mb centromeric likely gives risk to significant chromosome 17 
regional ALD. We identified three other chromosomal regions contributing significant IBD 
risk from European admixture. We replicated Maximal-CIS SNPs for NOD2, IL23R, 5p13.1, 
and FCGR2A, identified additional risk variants at 5p13.1and IL23R. We observed a strong 
correlation in ORs for Maximal-CIS SNPs between our study and the CIS suggesting that 
additional Caucasian established loci likely play a role in AAs. We also demonstrated other 
known (IL12B) and novel (C2orf43, HDAC11 and LINC00994) suggestive areas of 
association interest. The new suggestive associations will need to be validated by 
independent replication. Finally a network analysis showed that, as in other studies, 
cytokines, Jak-STAT signaling and chemokine pathways play major roles, but also suggests 
that measles and African trypanosomiasis pathways may be important for further 
investigation. This study has yielded vital information not only on the etiopathogenesis of 
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IBD specifically for AAs, but also about risk variants and ancestral chromosomal regions 
that may also contribute to IBD pathogenesis in Caucasians, as we continue our exploration 
of AA IBD genetics.
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Comparison of log2(Odds ratios) estimated in this study with those in Caucasian 
Immunochip Study (CIS) for 110 IBD-general (correlation=0.78), 26 CD-specific 
(correlation=0.77) and 23 UC-specific (correlation=0.61) Maximal-CIS SNPs.
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Association mapping (left) and admixture (right) mapping p-values (in −log10) for IBD (top 
panel), CD (middle panel) and UC (bottom panel).
Huang et al. Page 18













Huang et al. Page 19














Comparison of log10(Odds Ratios) at the risk alleles by chromosomal position (in Mb, 
Genome Build 37) between Caucasian (black), East Asian (green) and African American 
(red) loci for IBD (hatched), CD (solid) and UC (stippled). Bars with black outlines 
represent loci with reported genome-wide significant association evidence in the CIS (black, 
limited to OR≥1.1) or in East Asian studies (green). Bars without outlines are present for 
AA or East Asian replications (at p<3.1e-4) of CIS-Maximal SNPs, or for SNPs evaluated in 
these populations with suggestive evidence for association at established CIS loci (p<4.2e-5) 
or borderline of genome-wide significance for novel loci (p≤1e-6). Asterisks denote the 
same associated SNPs in AA and additional populations. Red arrows denote overlaps 
between significant admixture regions and association loci.
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Table 4
Significant KEGG pathways for IBD, CD and UC










Cytokine-cytokine receptor interaction IBD 12 1.55E-12 3.66E-10 3.66E-10
Jak-STAT signaling pathway IBD 8 4.07E-09 4.82E-07 9.64E-07
Chemokine signaling pathway IBD 8 1.59E-08 1.26E-06 3.77E-06
Measles IBD 7 3.32E-08 1.97E-06 7.88E-06
Pathways in cancer IBD 9 8.65E-08 4.10E-06 2.05E-05
T cell receptor signaling pathway IBD 5 6.33E-06 2.50E-04 1.50E-03
Focal adhesion IBD 6 9.10E-06 3.08E-04 2.16E-03
Gap junction IBD 4 5.97E-05 1.77E-03 1.42E-02
Fc gamma R-mediated phagocytosis IBD 4 7.47E-05 1.97E-03 1.77E-02
Vascular smooth muscle contraction IBD 4 1.74E-04 4.13E-03 4.13E-02
Cytokine-cytokine receptor interaction CD 18 3.11E-21 7.37E-19 7.37E-19
Chemokine signaling pathway CD 10 4.13E-11 4.89E-09 9.79E-09
Jak-STAT signaling pathway CD 9 2.29E-10 1.81E-08 5.42E-08
Measles CD 6 1.15E-06 6.84E-05 2.74E-04
Pathways in cancer CD 8 1.76E-06 8.32E-05 4.16E-04
Measles UC 7 1.97E-09 4.67E-07 4.67E-07
Cytokine-cytokine receptor interaction UC 8 1.03E-08 1.22E-06 2.43E-06
Jak-STAT signaling pathway UC 6 2.05E-07 1.62E-05 4.87E-05
T cell receptor signaling pathway UC 5 8.88E-07 5.26E-05 2.11E-04
African trypanosomiasis UC 3 2.33E-05 1.11E-03 5.53E-03
NOD-like receptor signaling pathway UC 3 1.15E-04 4.56E-03 2.74E-02




Number of genes in the pathway;
c
Nominal p-value, false discovery rate (FDR), and Bonferroni-corrected p-value respectively.
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